Intermittent Dosing of Dabrafenib and Trametinib in Metastatic BRAFV600E Mutated Papillary Thyroid Cancer: Two Case Reports
Sign Up to like & getrecommendations! Published in 2017 at "Thyroid"
DOI: 10.1089/thy.2017.0106
Abstract: Background: A multi-institutional, randomized phase II trial of continuous dosing of dabrafenib with or without trametinib is ongoing in metastatic thyroid cancer. Preclinical evidence and emerging clinical experience in other cancers support evaluating intermittent dosing… read more here.
Keywords: mutated papillary; papillary thyroid; thyroid cancer; intermittent dosing ... See more keywords
Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in BRAFV600E-Mutated Anaplastic Thyroid Carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Thyroid"
DOI: 10.1089/thy.2019.0133
Abstract: Background: When achieved, complete surgical resection improves outcomes in anaplastic thyroid carcinoma (ATC). However, most ATC patients present with advanced inoperable disease, often with impending airway obstruction, increased hemorrhage risk, and significant dysphagia. Novel treatment… read more here.
Keywords: surgical resection; complete surgical; thyroid carcinoma; brafv600e mutated ... See more keywords
Abstract 3958: FAK inhibition reduces tumor infiltration of Tregs via restricting CCL5 release and boosts the present therapeutic regimen for BRAFV600E-mutated colorectal carcinoma
Sign Up to like & getrecommendations! Published in 2019 at "Immunology"
DOI: 10.1158/1538-7445.am2019-3958
Abstract: Background: BRAFV600E-mutated colorectal carcinoma (CRC) is a refractory disease with poor prognosis and limited therapeutic approaches. Recently, researches have indicated that the recruitment of Tregs in tumor tissue promoted by BRAFV600E is responsible for the… read more here.
Keywords: brafv600e mutated; mutated crc; fak; tumor ... See more keywords
Abstract CT083: Tumor-agnostic efficacy and safety of dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: ROAR basket study
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct083
Abstract: Beyond melanoma, BRAFV600E alterations are prevalent across multiple tumors. We conducted a basket trial (NCT02034110) to assess efficacy and safety of oral BRAF inhibitor dabrafenib (150 mg BD) plus MEK inhibitor trametinib (2 mg OD)… read more here.
Keywords: reached reached; safety; rare cancers; brafv600e mutated ... See more keywords
Ongoing complete response after treatment cessation with dabrafenib, trametinib, and cetuximab as third-line treatment in a patient with advanced BRAFV600E mutated, microsatellite-stable colon cancer: A case report and literature review
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2023.1166545
Abstract: Metastatic BRAFV600E mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAFV600E mutated colorectal cancer have the… read more here.
Keywords: microsatellite stable; patient; brafv600e mutated; treatment ... See more keywords
Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms19040969
Abstract: The BRAFV600E mutation, which in melanoma is targetable with vemurafenib, is also found in sarcomas and we here evaluate the therapeutic potential in sarcoma cell lines. Methods: Four sarcoma cell lines harboring the BRAFV600E mutation,… read more here.
Keywords: sarcoma; cell lines; brafv600e; vemurafenib ... See more keywords